During AML development, the repertoire of NK cells is modified, reducing the expression of activating receptors, NKG2D, DNAX accessory molecule-1 (DNAM-1), natural cytotoxicity triggering receptor 3 (NKp30), NKp46 (41), and increasing that of inhibitory receptors, killer Ig-like receptors (KIRs), and natural killer group 2A (NKG2A). The gene discussed is NCR3; the disease is acute myeloid leukemia.